Research statistics
GH Fragment 176-191 research: publications and trials
At a glance
Publications, all years
2
Since 2022
Publications in 2026 so far
1
Through November 15, 2026
Human clinical research
0.0%
0 of 2 classified
Registered clinical trials
0
ClinicalTrials.gov
Randomized controlled trials
0
Publications reporting an RCT in people
Systematic reviews and meta-analyses
0
Preclinical studies
100.0%
0 animal · 2 in vitro · 0 computational
Records that only mention it
1
Not counted above
Status in the library: Research only. Groups: Growth hormone axis.
What to keep in mind
- No human clinical publication is indexed: everything published so far is preclinical, a review or commentary.
- Fewer than three randomized controlled trials are indexed.
- More than 70% of the indexed publications are animal, cell or computational studies.
- Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
Publications by year
GH Fragment 176-191 publications by year and evidence
Show the data
| Year | Preclinical (animal, in vitro, computational) |
|---|---|
| 2022 | 1 |
| 2026 (to date) | 1 |
Study types
| In vitro study | 2 |
|---|
Research areas
From MeSH major topics. A paper can be in several areas.
| Dermatology | 1 |
|---|---|
| Endocrinology | 1 |
| Oncology | 1 |
Registered clinical trials
A registration is not a result.
No registered trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
No human trial, systematic review or meta-analysis of GH Fragment 176-191 is indexed.
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.
Drug design, development and therapy · June 27, 2022 · In vitro study · cited 13 times · open access
PMID 35783198 · DOI 10.2147/dddt.s367586 · In vitro studies
- Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
The Analyst · July 27, 2026 · In vitro study · cited 0 times
PMID 42328738 · DOI 10.1039/d6an00455e · In vitro studies
Latest publications
- Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
The Analyst · July 27, 2026 · In vitro study · cited 0 times
PMID 42328738 · DOI 10.1039/d6an00455e · In vitro studies
- Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.
Drug design, development and therapy · June 27, 2022 · In vitro study · cited 13 times · open access
PMID 35783198 · DOI 10.2147/dddt.s367586 · In vitro studies
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Fragment 176-191; GH Fragment 176-191; hGH 176-191; HGH Frag; HGH Frag 176-191; HGH Fragment 176-191
((TITLE_ABS:"Fragment 176-191" OR CHEM:"Fragment 176-191" OR TITLE_ABS:"Fragment176-191" OR CHEM:"Fragment176-191") OR (TITLE_ABS:"GH Fragment 176-191" OR CHEM:"GH Fragment 176-191" OR TITLE_ABS:"GH Fragment176-191" OR CHEM:"GH Fragment176-191") OR (TITLE_ABS:"hGH 176-191" OR CHEM:"hGH 176-191" OR TITLE_ABS:"hGH176-191" OR CHEM:"hGH176-191") OR (TITLE_ABS:"HGH Frag" OR CHEM:"HGH Frag") OR (TITLE_ABS:"HGH Frag 176-191" OR CHEM:"HGH Frag 176-191" OR TITLE_ABS:"HGH Frag176-191" OR CHEM:"HGH Frag176-191") OR (TITLE_ABS:"HGH Fragment 176-191" OR CHEM:"HGH Fragment 176-191" OR TITLE_ABS:"HGH Fragment176-191" OR CHEM:"HGH Fragment176-191")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). GH Fragment 176-191 research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/gh-frag-176-191